Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.
Lohmann
C P
CP
Kroher
G
G
Bogenrieder
T
T
Spiegel
D
D
Preuner
J
J
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000628:therapy*; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000209:etiology*; D011994:Recombinant Proteins; D012878:Skin Neoplasms / Q000628:therapy*; D014786:Vision Disorders / Q000209:etiology*; D014792:Visual Acuity
D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins